Verrica Pharmaceuticals Inc
VRCA5.650USD
+0.010+0.18%
取引時間 （ET）15分遅れの株価
518.61M時価総額
損失額直近12ヶ月PER
詳細情報 Verrica Pharmaceuticals Inc 企業名
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
企業情報
企業コードVRCA
会社名Verrica Pharmaceuticals Inc
上場日Jun 15, 2018
最高経営責任者「CEO」Dr. Jayson Rieger
従業員数71
証券種類Ordinary Share
決算期末Jun 15
本社所在地44 West Gay Street
都市WEST CHESTER
証券取引所NASDAQ Global Market Consolidated
国United States of America
郵便番号19380
電話番号14844533300
ウェブサイトhttps://verrica.com/
企業コードVRCA
上場日Jun 15, 2018
最高経営責任者「CEO」Dr. Jayson Rieger
役員一覧
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
Mr. John J. Kirby
Mr. John J. Kirby
Interim Chief Financial Officer, Interim Principal Financial Officer
Interim Chief Financial Officer, Interim Principal Financial Officer
--
--
Mr. Paul B. Manning
Mr. Paul B. Manning
Chairman of the Board
Chairman of the Board
--
--
Mr. Mark A. Prygocki, Sr.
Mr. Mark A. Prygocki, Sr.
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Jayson Rieger
Dr. Jayson Rieger
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
88.99K
+50.90%
Mr. David Zawitz
Mr. David Zawitz
Chief Operating Officer
Chief Operating Officer
11.00K
--
Dr. Diem Nguyen, Ph.D.
Dr. Diem Nguyen, Ph.D.
Independent Director
Independent Director
10.00
--
Dr. Gavin Corcoran
Dr. Gavin Corcoran
Independent Director
Independent Director
2.00
--
Dr. Noah L. Rosenberg, M.D.
Dr. Noah L. Rosenberg, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Lawrence Eichenfield, M.D.
Dr. Lawrence Eichenfield, M.D.
Independent Director
Independent Director
--
--
収益内訳
データなし
データなし
事業別
地域別
データなし
株主
更新時刻: Fri, May 16
更新時刻: Fri, May 16
株主統計
種類
株主統計
株主統計
比率
Manning (Paul B.)
53.85%
Caligan Partners, LP
9.72%
Armistice Capital LLC
9.26%
BKB Growth Investments LLC
6.46%
Boothbay Fund Management, LLC
3.04%
Other
17.67%
株主統計
株主統計
比率
Manning (Paul B.)
53.85%
Caligan Partners, LP
9.72%
Armistice Capital LLC
9.26%
BKB Growth Investments LLC
6.46%
Boothbay Fund Management, LLC
3.04%
Other
17.67%
種類
株主統計
比率
Individual Investor
57.67%
Hedge Fund
19.53%
Investment Advisor
6.74%
Corporation
6.74%
Investment Advisor/Hedge Fund
5.58%
Research Firm
0.28%
Venture Capital
0.06%
Bank and Trust
0.04%
Pension Fund
0.01%
Other
3.35%
機関投資家保有株
更新時刻: Tue, Jul 1
更新時刻: Tue, Jul 1
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q2
182
8.94M
96.65%
+3.24M
2025Q1
194
69.94M
75.99%
+19.16M
2024Q4
191
70.39M
77.72%
+35.42M
2024Q3
179
29.67M
67.28%
-5.27M
2024Q2
173
33.68M
79.75%
-1.13M
2024Q1
171
34.51M
82.01%
-2.46M
2023Q4
170
35.04M
83.66%
+1.56M
2023Q3
172
32.74M
78.91%
-2.85M
2023Q2
169
31.35M
77.69%
+2.98M
2023Q1
171
29.74M
73.94%
+2.67M
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Manning (Paul B.)
31.38M
33.93%
+17.53M
+126.54%
Nov 26, 2024
Caligan Partners, LP
8.99M
9.72%
+1.56M
+21.04%
Mar 31, 2025
Armistice Capital LLC
8.57M
9.26%
-353.60K
-3.96%
Mar 31, 2025
BKB Growth Investments LLC
5.98M
6.46%
+5.98M
--
Nov 22, 2024
Boothbay Fund Management, LLC
2.81M
3.04%
+220.30K
+8.52%
Mar 31, 2025
The Vanguard Group, Inc.
2.36M
2.55%
+481.41K
+25.61%
Mar 31, 2025
Stalfort (John A)
1.87M
2.03%
+238.09K
+14.56%
Apr 01, 2025
BlackRock Institutional Trust Company, N.A.
1.12M
1.22%
+32.58K
+2.98%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.02M
1.1%
+541.22K
+113.40%
Mar 31, 2025
Rieger (Jayson)
889.88K
0.96%
+300.19K
+50.91%
Apr 01, 2025
詳細を見る
関連ETF
更新時刻: Sat, Aug 2
更新時刻: Sat, Aug 2
銘柄名
比率
Invesco NASDAQ Future Gen 200 ETF
0%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
0%
Simplify Propel Opportunities ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
詳細を見る
Invesco NASDAQ Future Gen 200 ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%
Global X Russell 2000 ETF
比率0%
Proshares Ultra Russell 2000
比率0%
Avantis US Small Cap Equity ETF
比率0%
iShares Micro-Cap ETF
比率0%
Simplify Propel Opportunities ETF
比率0%
iShares Russell 2000 ETF
比率0%
ProShares Hedge Replication ETF
比率0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
種類
比率
データなし
日付
種類
比率
データなし
